Ziv-aflibercept
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
HTNGLOMTMA
ModerateOpen →
Anti-VEGFR2 antibody
Ramucirumab
Cyramza · Ramu
A VEGFR2-blocking antibody that strips the glomerular endothelium of VEGF, driving hypertension and proteinuria.
ModerateAnti-VEGFR2 monoclonal antibody · approved 2014
Gastric / gastroesophageal junction adenocarcinomaMetastatic colorectal cancerNon-small-cell lung cancerHepatocellular carcinoma
Signature kidney injury
Hypertension
Hypertension and proteinuria are common class effects; nephrotic syndrome is a less frequent but reported event, sometimes after only 1-2 doses and typically accompanied by hypertension.
Source: Fujii et al., Medicine (Baltimore) 2019
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
GlomerulusFiltration barrier (podocytes + endothelium)
Vasculature / EndotheliumGlomerular & peritubular capillaries
Hypertension
On-target loss of endothelial nitric oxide from VEGF-pathway blockade — so consistent it marks drug activity.
Mechanism of kidney injury
Blockade of VEGFR2 on glomerular endothelium and podocyte-derived VEGF signaling disrupts the constitutive paracrine podocyte-to-endothelium VEGF axis required to maintain fenestrated glomerular endothelium and the slit diaphragm. The result is endothelial swelling (endotheliosis), loss of fenestrae, reduced nitric-oxide-mediated vasodilation (hypertension), proteinuria, and — in severe cases — a renal-limited thrombotic microangiopathy with fibrin thrombi. The mechanism parallels the podocyte-specific VEGF-knockout phenotype demonstrated experimentally.
Clinical presentation
New or worsening hypertension and proteinuria; nephrotic-range proteinuria with edema and sometimes a creatinine rise. Biopsy, when performed, shows glomerular endotheliosis/TMA (double contours, mesangiolysis) with variable foot-process effacement.
Onset
Within the first one to two cycles (weeks).
Reversibility
Reversible
Anticancer mechanism
Fully human IgG1 monoclonal antibody that binds the extracellular domain of VEGF receptor 2 (VEGFR2/KDR), blocking ligand binding by VEGF-A, VEGF-C and VEGF-D and inhibiting receptor activation, downstream signaling and tumor angiogenesis. Used in gastric/GEJ, colorectal, hepatocellular and non-small-cell lung cancers.
Management
Control hypertension (ACE inhibitor/ARB preferred to also reduce proteinuria); per label, interrupt for urine protein >=2 g/24 h and reduce the dose on resumption, and permanently discontinue for urine protein >3 g/24 h, nephrotic syndrome, or any TMA. Proteinuria and hypertension generally improve after dose interruption or withdrawal.
Risk factors
- Pre-existing hypertension
- Pre-existing chronic kidney disease or proteinuria
- Diabetes
Prevention
- Baseline and periodic blood pressure and urine protein (UPCR/dipstick) monitoring
- Optimize blood pressure control before and during therapy
Note · Renal effects are a shared VEGF-pathway class effect; reversibility with early discontinuation is well described, but TMA can occur and warrants permanent discontinuation.
Clinical depth
Renal dose adjustment
No pharmacokinetic renal dose adjustment is required for a monoclonal antibody, but dosing is modified by toxicity: interrupt/reduce for grade 3 hypertension until controlled and for proteinuria thresholds above. Renal impairment does not alter antibody clearance.
Dialyzability & ESKD dosing
Not dialyzable — a ~147 kDa IgG1 monoclonal antibody is not removed by hemodialysis or peritoneal dialysis; no dose change is needed for dialysis patients.
Differential diagnosis
Anti-VEGF glomerular injury (hypertension + proteinuria + endotheliosis/TMA on biopsy) versus prerenal AKI, versus minimal change/FSGS seen more with VEGFR-TKIs, versus a paraneoplastic membranous nephropathy. The temporal link to dosing and accompanying hypertension favor the drug; biopsy confirms TMA.
Monitoring
- Blood pressure every 2 weeks or with each infusion
- Urine protein (dipstick/UPCR) before dosing; quantify with 24-h collection if >=2+
- Serum creatinine periodically; CBC/LDH if TMA suspected
Key trials & series
- REGARD (gastric, Lancet 2014) and RAINBOW (gastric + paclitaxel, Lancet Oncol 2014) — registrational trials reporting hypertension/proteinuria
- Fujii et al. single-center nephrotic-syndrome case series (Medicine 2019)
Clinical pearls
- Anti-VEGF antibodies favor a TMA/endotheliosis pattern, whereas oral VEGFR-TKIs more often cause MCD/FSGS — the biopsy pattern hints at the culprit class.
- Use an ACE inhibitor or ARB to treat both the hypertension and the proteinuria.
- Permanently stop for nephrotic syndrome or TMA; lesser proteinuria can be managed by interruption and dose reduction.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Glomerulus
Filtration barrier (podocytes + endothelium)
Injury signatures
HypertensionGlomerular Injury / ProteinuriaThrombotic Microangiopathy
Beyond the kidney
Class-level context for the major non-renal toxicities of anti-vegfr2 antibodys.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkVEGF inhibition and renal thrombotic microangiopathy.Eremina V et al. · N Engl J Med 2008 · PMID 18337603Landmark paper proving VEGF inhibition (anti-VEGF antibody and podocyte VEGF knockout) directly causes renal TMA.PMIDNephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review.Fujii T et al. · Medicine (Baltimore) 2019 · PMID 31277139Case series of ramucirumab-associated nephrotic syndrome with hypertension; biopsy and outcomes.PMIDTherapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.Estrada CC et al. · J Am Soc Nephrol 2019 · PMID 30642877Mechanistic review: direct VEGF/VEGFR2 inhibition is linked to renal-limited TMA.PMIDThe Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".Sanidas E et al. · Am J Hypertens 2018 · PMID 29788148Reviews the pathophysiology (reduced NO, microvascular rarefaction) and management of antiangiogenic hypertension.PMID[Nephrotoxicity of anti-angiogenesis drugs].Grechukhina KS et al. · Ter Arkh 2020 · PMID 33346501Review of antiangiogenic nephrotoxicity naming ramucirumab and its TMA pattern.PMIDProteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.Tesarova P et al. · Folia Biol (Praha) 2013 · PMID 23537524Class review of anti-VEGF proteinuria/hypertension incidence, mechanisms and management.
Related agents
Other agents sharing the same signature kidney injury.